Biomolecule | Nanomaterials | method | Advantage | Type of cancer cell | Â |
---|---|---|---|---|---|
Peptide | AuNPs | PTT | Enhances the PTT efficiency of gold nanoparticles for furin-related cancer | MDA-MB-468 cell | [106] |
pH-sensitively zwitterionic polypeptide conjugated GNRs | PTT | Excellent biocompatibility against normal and cell pH-sensitively released the drugs under tumoral acid condition | HeLa cells | [107] | |
cRGD@TAT-DINPs | CT/PTT/PDT | Excellent biological stability, combining multiple treatment methods | MDA-MB-231 and A549 cell | [131] | |
CD133-Pyro | PDT | More effective targeted and intraocyric accumulation effects | Colorectal cancer cells | [132] | |
IR780-M-APP NPs | PDT/immunotherapy | Targeted tumors and eradicated the metastatic and invasive tumors effectively | B16F10 cell | [134] | |
Protein | E72-Chitosan-Ag3AuS2 hybrid hydrogel | PTT | High biocompatibility and photothermal conversion efficiency | Tongue cancer cell | [109] |
BSA-Ag2S NPs | PTT | Biocompatibility | HeLa cells | [110] | |
Tf-RuNPs | PTT | Biocompatibility and stability | HEK-293 cell | [111] | |
Ce6/Cyt c @ZIF-8/HA NPs | PDT | Overcomes the PDT induced hypoxia to further increase PDT efficiency | HeLa cell and SMMC7721 cell | [135] | |
Bioinspired oxygen nanocarrier (C@HPOC) | PDT | Destroyed the primary tumors and effectively inhibited distant tumors and lung metastasis | 4T1 tumor cells | [136] | |
FA/PtBSA@MB-MSNS nanopolymers | PDT | Overcomes the PDT induced hypoxia to further increase PDT efficiency | 4T1 tumor cells | [137] | |
PDA | PhMOSN@DOX-HA | PTT/CL | Biocompatible and biodegradable | 4T1 tumor cell | [114] |
MoSe2@PDA nanocomposites | PTT/CL | High loading efficiency and pH-responsive Dox release effect | U14 cell | [115] | |
PDA@DOX NPs | PTT/CL | Targeted and high drug load | 4 T1 tumor cell | [116] | |
PDA-Dox-Pc-QRH NPs | PDT/CT | Chemical photodynamic combined targeted therapy | A431 cell | [138] | |
MnO2-PDA nanoshell | PDT/CT | Has the effect of alleviating tumor hypoxia and enhancing the PDT effect | B16F10 cell | [139] | |
RNA | CuS-RNP/DOX@PEI | PTT/GT/ CT | Provides a potential strategy to reduce tumor thermal tolerance for enhanced mild-PTT effects | A375 cell | [119] |
PPTC/siRNA | PDT | ROS-responsive siRNA release mode, PDT combined with RNAi to improve the therapeutic efficiency | HepG2 cells | [144] | |
DNA | DNA-UCNP-Au hydrogels | PTT | Low cytotoxicity and injectable properties allow local therapy to precisely target the tumor site | T24 bladder cancer cell | [121] |
UCNP-ApDz-TMPyP4 Nanoplatform | PTT | Combining PDT with gene therapy shows excellent antitumor effect | Catalysis | [141] | |
DNA Nanosponge | PDT/GT | Effective against hypoxia-related photodynamic resistance during PDT in vivo with good biocompatibility | HeLa cells | [142] | |
Enzyme | GOIGLs (GOx) | PTT | Achieves milder PTT with good biocompatibility | A549 cell | [124] |
PMF−GOx | PTT/CDT | Fenton reaction and moderatehyperthermia cancer treatment together | MCF-7 tumor cell | [125] | |
NC@GOx NPs | PTT/CDT | Combination therapy of starvation therapy, PTT and CDT for tumors | 4T1 tumor cell | [126] | |
MYR@HGNs (MYR) | PTT | Protect and activate the encapsulated enzymes for localized chemo-photothermal therapy | 4T1 tumor cell | [127] | |
HA-CAT@aCe6 (CAT)) | PDT | Overcome tumor cell hypoxia during PDT and improve the therapeutic effect of PDT | MDA-MB-231 cell | [146] | |
GOx-MSN@MnPc-LP | PDT | Good enzyme activity, and good therapeutic effect and safety through the synergistic treatment | 4T1 tumor cell | [147] | |
nanogel | PDT | Provide a new method for constructing combinatorial therapeutics with good tumor targeting ability and efficient anti-cancer effect | 4T1 tumor cell | [148] |